Lower extremity XXXX in @entity309 : features and response to immunosuppression.

@entity1 @entity66 @entity39 @entity5 @entity310 @entity1066 @entity309
Lower extremity @entity1066 are a recognized complication of @entity309 ( @entity309 ). Their prevalence has not been assessed since the advent of more aggressive disease modifying antirheumatic therapies. The purpose of this study was to establish the period prevalence of lower extremity @entity1066 in a modern-day unselected cohort of @entity1 with @entity309 , and to report the features associated with @entity1066 development and response to therapy. Between June 2007 and June 2010, 366 @entity309 @entity1 were evaluated at the Georgetown Division of Rheumatology. Data were collected and analyzed retrospectively on demographics, antibody and prothrombotic profile, comorbidities, disease activity, and outcomes. The period prevalence of @entity1066 in this cohort of 366 @entity1 with @entity309 followed over 3  years was 4.37%. @entity1 with @entity1066 were predominantly female (81.25%) and more commonly African American (56.2%). The mean disease duration at @entity1066 development was 25.9  years. All @entity1 with @entity1066 had @entity66 and 63% were seropositive. Only five @entity1 (31.25%) healed over a mean follow-up of 22.8  months. However, in this small sample, treatment with anti- @entity5 @entity39 factor-a (anti- @entity310 ) therapy was associated with significantly higher likelihood of healing (p   =   0.039). In this modern-day cohort of @entity1 with @entity309 , we found a prevalence of lower extremity @entity1066 of 4.37% over 3  years. Only 31.25% of @entity1 healed after a mean 22.8  months of follow-up. However, treatment with a biologic agent was associated with a significant increased likelihood of healing (RR 3.27, 95% CI 0.59-18.29, p   =   0.039).
